• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

AI-Driven Drug Discovery Startup Unnatural Products Nabs $6M

by Jasmine Pennic 09/17/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

ARTIS Ventures Backs AI-Driven Drug Discovery Startup Unnatural Products

– Drug discovery startup Unnatural Products, Inc. pairing AI with chemistry to create treatments for drug targets raise $6M in funding led by ARTIS Ventures.

– Unnatural Products uses a combination of machine learning and parallel chemistry to change the way we think about treating disease

 

Today ARTIS Ventures has led a $6 million seed round for Unnatural Products, Inc., a Santa Cruz, CA-based drug discovery startup pairing AI with chemistry to create treatments for drug targets that aren’t amenable to our current therapeutic strategies. Other investors include Abstract Ventures, Asset Management Ventures, Better Ventures, Blue Bear Ventures, and Rising Tide Fund.

The company is currently focused on oncology, though their technology can be applied to a wide variety of urgent clinical needs such as inflammatory diseases. The funds will be used to grow the team, continue platform development, and push forward the company’s pipeline of oncology programs.

UNP has created a unique platform that closely marries prediction with experiment. This rapid, intelligent learning loop has allowed UNP to solve key challenges, such as cell permeability, that have previously been the roadblock in macrocycle development. Though currently focused on select oncology targets, this technology can be applied to a wide variety of urgent clinical needs such as inflammatory diseases. 

Why It Matters

“UNP’s machine-led discovery of macrocycle drugs combined with their chemistry platform is a unique approach in the drug discovery space,” said Vasudev Bailey, PhD, partner at ARTIS Ventures. “This has the potential to hugely impact drug development with the ability to address the 80 percent of drug targets for which there are currently no therapeutic strategies.”

“In many ways our understanding of human biology, particularly in the role of certain drivers of cancer, has outstripped our chemistry capabilities,” said Cameron Pye, CEO and co-founder of Unnatural Products, Inc. “At UNP, we’re focused on one of nature’s solutions to this problem, macrocycles, to expand our chemical toolbox. A lot of the high-hanging fruit in drug discovery has been called ‘undruggable,’ and we’re working to change that.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

HLTH 2025 Coverage

HLTH 2025 Day 1 Summary & Insights: AMA Launches AI Governance Center, Google Cloud, Microsoft, ChatGPT for Medicine

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Northwell Health Selects to Deploy Abridge’s Ambient AI Across 28 Hospitals

Northwell Health to Deploy Abridge’s Ambient AI Across 28 Hospitals

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |